British journal of cancer · 1999

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, Vansteenkiste JF, Rosso R, Ewers SB, Sundal E, Schatzmann E, Stocker H

Аннотация

Anaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetin alpha in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4-6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (n = 44), epoetin alpha 150 IU kg(-1) subcutaneously (s.c.) three times a week (n = 42) or 300 IU kg(-1) s.c. three times a week (n = 44). Reductions in epoetin alpha dosage were made during the study if Hb level increased to >15 g dl(-1). The mean weekly dosage was 335 and 612 IU kg(-1), respectively, in the two active treatment groups. Significantly fewer (P < 0.05) epoetin alpha-treated patients experienced anaemia (Hb < 10 g dl(-1)) during the course of chemotherapy (300 IU kg(-1), 39%; 150 IU kg(-1), 48%; untreated, 66%). This was reflected in the significantly lower number of treated patients transfused [300 IU kg(-1), 20% (P< 0.001); 150 IU kg(-1), 45% (P< 0.05); untreated, 59%]. Epoetin alpha was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin alpha is effective and well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Abels R. Erythropoietin for anaemia in cancer patients. 29A Suppl 2 1993 S2 S8 Eur J Cancer 8398361 10.1016/s0959-8049(05)80281-3

Baer A. N. Dessypris E. N. Goldwasser E. Krantz S. B. Blunted erythropoietin response to anaemia in rheumatoid arthritis. 66 4 8 1987 559 564 Br J Haematol 3663512 10.1111/j.1365-2141.1987.tb01344.x

Blumberg N. Heal J. M. Effects of transfusion on immune function. Cancer recurrence and infection. 118 4 4 1994 371 379 Arch Pathol Lab Med 8166587

Canetta R. Rozencweig M. Carter S. K. Carboplatin: the clinical spectrum to date. 12 Suppl A 9 1985 125 136 Cancer Treat Rev 3002623 10.1016/0305-7372(85)90027-1

Cascinu S. Fedeli A. Fedeli S. L. Catalano G. Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. 67 1 1 1993 156 158 Br J Cancer PMC1968216 8427776 10.1038/bjc.1993.27

Case D. C. Jr Bukowski R. M. Carey R. W. Fishkin E. H. Henry D. H. Jacobson R. J. Jones S. E. Keller A. M. Kugler J. W. Nichols C. R. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. 85 10 19 5 1993 801 806 J Natl Cancer Inst 8487324 10.1093/jnci/85.10.801

Del Mastro L. Venturini M. Lionetto R. Garrone O. Melioli G. Pasquetti W. Sertoli M. R. Bertelli G. Canavese G. Costantini M. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. 15 7 7 1997 2715 2721 J Clin Oncol 9215845 10.1200/JCO.1997.15.7.2715

Eschbach J. W. Egrie J. C. Downing M. R. Browne J. K. Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. 316 2 8 1 1987 73 78 N Engl J Med 3537801 10.1056/NEJM198701083160203

Gebbia V. Valenza R. Rausa L. The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells. 10 6 Nov-Dec 1990 1779 1782 Anticancer Res 2285259

Glaspy J. Bukowski R. Steinberg D. Taylor C. Tchekmedyian S. Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. 15 3 3 1997 1218 1234 J Clin Oncol 9060566 10.1200/JCO.1997.15.3.1218

Hesketh P. J. Cooley T. P. Finkel H. E. Wright J. Hesketh A. M. Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil, and mitomycin C. 62 8 15 10 1988 1466 1470 Cancer 2844381 10.1002/1097-0142(19881015)62:8<1466::aid-cncr2820620803>3.0.co;2-#

Kaye S. B. Lewis C. R. Paul J. Duncan I. D. Gordon H. K. Kitchener H. C. Cruickshank D. J. Atkinson R. J. Soukop M. Rankin E. M. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. 340 8815 8 8 1992 329 333 Lancet 1353804 10.1016/0140-6736(92)91404-v

Kuzur M. E. Greco F. A. Cisplatin-induced anemia. 303 2 10 7 1980 110 111 N Engl J Med 7189822 10.1056/NEJM198007103030215

Ludwig H. Fritz E. Kotzmann H. Höcker P. Gisslinger H. Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. 322 24 14 6 1990 1693 1699 N Engl J Med 2342535 10.1056/NEJM199006143222402

Ludwig H. Leitgeb C. Fritz E. Krainer M. Kührer I. Kornek G. Sagaster P. Weissmann A. Erythropoietin treatment of chronic anaemia of cancer. 29A Suppl 2 1993 S8 12 Eur J Cancer 8398362 10.1016/s0959-8049(05)80282-5

Ludwig H. Pecherstorfer M. Leitgeb C. Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. 11 5 9 1993 348 355 Stem Cells 8241947 10.1002/stem.5530110502

Miller A. B. Hoogstraten B. Staquet M. Winkler A. Reporting results of cancer treatment. 47 1 1 1 1981 207 214 Cancer 7459811 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6

Miller C. B. Jones R. J. Piantadosi S. Abeloff M. D. Spivak J. L. Decreased erythropoietin response in patients with the anemia of cancer. 322 24 14 6 1990 1689 1692 N Engl J Med 2342534 10.1056/NEJM199006143222401

Rothmann S. A. Paul P. Weick J. K. McIntyre W. R. Fantelli F. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. 3 6 11 1985 415 423 Int J Cell Cloning 4067362 10.1002/stem.5530030607

Skillings J. R. Sridhar F. G. Wong C. Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. 16 1 2 1993 22 25 Am J Clin Oncol 8424398 10.1097/00000421-199302000-00006

Walker R. H. Special report: transfusion risks. 88 3 9 1987 374 378 Am J Clin Pathol 3630978 10.1093/ajcp/88.3.374

de Campos E. Radford J. Steward W. Milroy R. Dougal M. Swindell R. Testa N. Thatcher N. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. 13 7 7 1995 1623 1631 J Clin Oncol 7602351 10.1200/JCO.1995.13.7.1623

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.

Ошибки и ограничения

Аннотация